3 results about "Dicaffeoylquinic acid" patented technology

This invention provides a method for extracting active ingredients from *Erigeron breviscapus*, belonging to the field of pharmaceutical technology. Based on the differences in the physicochemical properties of the compounds, this invention first achieves preliminary separation of caffeic acid esters and scutellarin, followed by further purification and separation based on the properties of the two types of substances. Specifically, this invention uses ethanol-water solutions of different concentrations to extract caffeic acid esters stepwise, and uses macroporous and microporous resins for preliminary separation of the caffeic acid esters. Scutellarin is then preliminarily separated through acid-base treatment. Finally, high-purity scutellarin, 3,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, and scutellarin are obtained through reversed-phase industrial chromatography. This invention achieves the extraction and separation of multiple active ingredients from *Erigeron breviscapus*, and all solvents used in the extraction and separation process are recyclable, resulting in low cost.

The application discloses application of 1,5-dicaffeoylquinic acid in prevention and / or treatment of non-alcoholic fatty liver disease and weight loss and blood lipid reduction, and belongs to the technical field of biological medicine. The application first proposes application of 1,5-dicaffeoylquinic acid in preparation of a medicine for preventing and / or treating metabolic related fatty diseases. In-vivo and in-vitro experimental results show that after 1,5-dicaffeoylquinic acid is used in an in-vitro and in-vivo NAFLD model, the weight can be reduced, liver function and blood lipid abnormality, sugar metabolism abnormality and lipid accumulation can be relieved; the 1,5-dicaffeoylquinic acid can be used for preparing a medicine for preventing or treating NAFLD, obesity and blood lipid reduction, and the new use of the 1,5-dicaffeoylquinic acid in resisting NAFLD is confirmed, so that the 1,5-dicaffeoylquinic acid is expected to be developed into a new type of NAFLD resisting medicine, and has a wide market prospect.

A steviol glycoside solubility enhancer may include a monocaffeoylquinic (MCQ) component that includes at least one compound selected from the group consisting of chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, and salts thereof; and a dicaffeoylquinic (DCQ) component that includes at least one compound selected from the group consisting of 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, and salts thereof. In one suitable implementation, the MCQ component and the DCQ component together comprise more than 50% (wt), preferably more than 60% (wt), more than 70% (wt), more than 80% (wt), more than 90% (wt), or more than 95% (wt) of the steviol glycoside solubility enhancer.